November 5, 2019
Sierra Oncology Reports Third Quarter 2019 Results
VANCOUVER, Nov. 4, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics for the treatment of patients ...
November 5, 2019
TYME Presents Business Update and Reports Second Quarter Fiscal 2020 Financial and Operating Results
NEW YORK, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating ...
November 5, 2019
DURECT Corporation Announces Third Quarter 2019 Financial Results and Update of Programs
CUPERTINO, Calif., Nov. 4, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) today announced financial results for the three months ended September 30, 2019 and provided a ...
November 5, 2019
Paratek Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12, 2019
BOSTON, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, ...
November 5, 2019
Bionano Genomics to Report Third Quarter 2019 Financial Results and Host a Conference Call and Webcast on November 7
SAN DIEGO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ...
November 5, 2019
Reata Pharmaceuticals, Inc. to Report Third Quarter 2019 Financial Results and to Provide an Update on Development Programs on November 12, 2019
IRVING, Texas, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and ...
November 5, 2019
Intercept Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update
NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to ...
November 5, 2019
Oncolytics Biotech(R) to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / November 5, 2019 / Oncolytics Biotech® Inc. (ONCY)(ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, ...
November 5, 2019
Axovant Gene Therapies Announces Investor Conference Presentations for the Remainder of 2019
NEW YORK and BASEL, Switzerland, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced ...
November 5, 2019
Cidara Therapeutics Hosting Key Opinion Leader Meeting on Rezafungin and Cloudbreak Programs
SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will ...
November 5, 2019
Cue Biopharma to Host Business Update Call and Webcast
CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively ...
November 5, 2019
BioLineRx Presents Preclinical Data From Triple Combination of BL-8040, Anti PD-1 and Chemotherapy Demonstrating Significant Reduction in Pancreatic Tumor Growth and Favorable Changes in Tumor Microenvironment
TEL AVIV, Israel, Nov. 5, 2019 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology, announced today positive preclinical results further ...
November 5, 2019
Compugen Presents Initial Clinical Data from Ongoing Phase 1 Trial of COM701 in Patients with Advanced Solid Tumors at SITC 2019
HOLON, Israel, Nov. 5, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today disclosed preliminary results from its ...
November 5, 2019
Celyad Highlights Abstracts from mCRC Clinical Program Released for SITC 34th Annual Meeting
MONT-SAINT-GUIBERT, Belgium, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of ...
November 5, 2019
Heat Biologics Reports Positive Phase 2 Interim Data in NSCLC Patients Who Previously Failed Checkpoint Inhibitor Treatment
DURHAM, NC / ACCESSWIRE / November 5, 2019 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system ...
November 5, 2019
InspireMD to Report Third Quarter 2019 Financial Results and Provide Business Update on Tuesday, November 12
TEL AVIV, Israel, Nov. 05, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention ...
November 5, 2019
Opiant Pharmaceuticals to Report Third Quarter 2019 Financial Results and Host Conference Call and Webcast on Tuesday, November 12
SANTA MONICA, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug ...
November 5, 2019
Genocea Presents Preclinical Research that Shows Inhibitory Neoantigens Stifle Protective Anti-Tumor Immune Responses at Society for Immunotherapy of Cancer (SITC)
CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced preclinical and clinical data demonstrating ...
November 5, 2019
Compugen Presents Preclinical Data for COM902 Anti-TIGIT Program at SITC 2019
HOLON, ISRAEL, Nov. 5, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today disclosed preclinical results from its ...
November 5, 2019
CohBar Completes Phase 1a and Initiates Phase 1b Stage of Clinical Trial of CB4211 Under Development for NASH and Obesity
MENLO PARK, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related ...
Page 129 of 172